News
AURA
6.42
-3.75%
-0.25
Weekly Report: what happened at AURA last week (0602-0606)?
Weekly Report · 6d ago
Weekly Report: what happened at AURA last week (0526-0530)?
Weekly Report · 06/02 11:16
Aura Biosciences Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 05/28 10:43
Aura Biosciences Price Target Announced at $22.00/Share by HC Wainwright & Co.
Dow Jones · 05/28 10:43
HC Wainwright & Co. Assumes Aura Biosciences at Buy, Announces Price Target of $22
Benzinga · 05/28 10:33
Innovative Precision Oncology and Promising Clinical Results Justify Buy Rating for Aura Biosciences Inc
TipRanks · 05/28 10:16
Aura Biosciences assumed with a Buy at H.C. Wainwright
TipRanks · 05/28 10:10
Weekly Report: what happened at AURA last week (0519-0523)?
Weekly Report · 05/26 11:15
Catalyst Watch: Eyes on Nvidia, OPEC, and box office blockbusters
Seeking Alpha · 05/23 19:00
Aura Biosciences Price Target Maintained With a $19.00/Share by JMP Securities
Dow Jones · 05/23 13:32
JMP Securities Reiterates Market Outperform on Aura Biosciences, Maintains $19 Price Target
Benzinga · 05/23 13:22
Strategic Positioning and Regulatory Advantage Bolster Aura Biosciences Inc’s Buy Rating
TipRanks · 05/23 08:17
Major Stock Moves: Aura Biosciences Inc Sees Insider Buying Spree!
TipRanks · 05/21 02:06
Aura Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters · 05/20 13:32
Weekly Report: what happened at AURA last week (0512-0516)?
Weekly Report · 05/19 11:06
Promising Developments and Strategic Advancements Propel Aura Biosciences Inc’s Buy Rating
TipRanks · 05/19 08:25
Aura Biosciences Advances in Cancer Therapy Trials
TipRanks · 05/17 03:54
Aura Biosciences Raises $69.9 Million in Public Offering
TipRanks · 05/16 20:41
Aura Biosciences: Strategic Advancements and Clinical Progress Drive Buy Rating
TipRanks · 05/16 13:45
Aura Biosciences Inc <AURA.OQ> expected to post a loss of 49 cents a share - Earnings Preview
Reuters · 05/16 12:54
More
Webull provides a variety of real-time AURA stock news. You can receive the latest news about Aura Biosciences, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AURA
Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. The Company’s lead candidate, bel-sar (AU-011), is in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer. It is developing bel-sar as a potential first-line vision-sparing treatment option for early intervention in small choroidal melanoma and/or indeterminate lesions, avoiding the need for radiotherapy and reducing the risk for metastasis for these patients. Bel-sar is a virus-like drug conjugate (VDC) consisting of a human papillomavirus (HPV)-derived virus-like particle (VLP) and a phthalocyanine dye, a light-activated cytotoxic payload. The Company’s platform is designed to enable the targeting of a broad range of solid tumors using VLP, that can be conjugated with drugs or loaded with nucleic acids to create VDCs.